Latest News and Press Releases

SAN DIEGO and TORONTO, May 02, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...

Dosing Initiated in CG-806 Phase 1 a/b Study in AML Patients at 450mg Dose Level Nodal Reductions Observed and Dosing Continues in CG-806 Phase 1 a/b Study in CLL Patients Dosing Continues in...

SAN DIEGO and TORONTO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...

SAN DIEGO and TORONTO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...

Oral FLT3/BTK inhibitor CG-806 expands development beyond B-cell malignancies to the treatment of AML Phase 1a/b study in B-cell malignancies continues through dose escalation SAN DIEGO and TORONTO,...

SAN DIEGO and TORONTO, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...

─  APTO-253 Inhibits MYC in AML and MDS Patients in Phase 1 Clinical Trial ─ ─  First CLL Patient Dosed with CG-806 in Phase 1 Clinical Trial ─ Conference Call and Webcast at 5pm EDT Today ...

 – CG-806 oral non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML  –  – APTO-253 MYC inhibitor being developed for the...

─  Patient Dosed at Second Dose Level in APTO-253 Clinical Trial ─ ─  Patient Screening Initiated for CG-806 Clinical Trial ─ Conference Call and Webcast at 5pm EDT Today SAN DIEGO and TORONTO, May...

– CG-806 highly potent, oral, non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML – – Phase 1 trial in relapsed or refractory...